title: Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia.
authors.forename: D
authors.initials: D
authors.lastname: Milojkovic
authors.forename: K
authors.initials: K
authors.lastname: Short
authors.forename: J R
authors.initials: JR
authors.lastname: Salisbury
authors.forename: D
authors.initials: D
authors.lastname: Creamer
authors.forename: A W P
authors.initials: AW
authors.lastname: du Vivier
authors.forename: G J
authors.initials: GJ
authors.lastname: Mufti
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D005260:Female; D006651:Histocytochemistry; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate